Close Menu

St. Jude

Two new analyses have identified driver genes, altered pathways, mutational signatures, and other molecular features across two dozen cancer subtypes.

A proportion of pediatric ALL patients appear to have germline TP53 mutations associated with later diagnoses, poorer outcomes, and increased secondary cancer risk.

Right Patient Right Drug will use the PharmacoScan platform to perform preventive pharmacogenetic testing under St. Jude's PG4KDS program.  

Genome and transcriptome sequences from hundreds of pediatric cancer cases led to somatic mutations and fusions suspected of producing potentially targetable antigens.

In Nature this week: new Neanderthal mitochondrial genome, and more.

Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

Suspicious variants were uncovered through analyses of pediatric cancer survivors from the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study.

Results from up to eight stages of mouse or human retina development highlight the importance of histone modifications and other epigenetic shifts during differentiation.

Roughly one-fifth of adult cases of acute lymphoblastic leukemia are marked by Philadelphia chromosome-like expression. 

Pages

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.